Humacyte, Inc. (NASDAQ:HUMA - Get Free Report) insider Shamik J. Parikh purchased 7,500 shares of Humacyte stock in a transaction that occurred on Thursday, April 10th. The shares were bought at an average cost of $1.55 per share, with a total value of $11,625.00. Following the completion of the transaction, the insider now directly owns 7,500 shares of the company's stock, valued at approximately $11,625. The trade was a ∞ increase in their position. The purchase was disclosed in a legal filing with the SEC, which is accessible through the SEC website.
Humacyte Price Performance
Shares of Humacyte stock opened at $1.49 on Tuesday. Humacyte, Inc. has a 1 year low of $1.15 and a 1 year high of $9.97. The company has a market capitalization of $231.13 million, a price-to-earnings ratio of -1.11 and a beta of 1.62. The business has a fifty day simple moving average of $2.81 and a two-hundred day simple moving average of $4.13.
Humacyte (NASDAQ:HUMA - Get Free Report) last posted its earnings results on Friday, March 28th. The company reported ($0.16) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.23) by $0.07. The company had revenue of $7.23 million for the quarter, compared to analyst estimates of $0.64 million. As a group, equities analysts anticipate that Humacyte, Inc. will post -1.27 earnings per share for the current fiscal year.
Wall Street Analyst Weigh In
HUMA has been the topic of a number of analyst reports. HC Wainwright reiterated a "buy" rating and set a $15.00 price objective on shares of Humacyte in a research note on Wednesday, March 12th. Benchmark reaffirmed a "buy" rating on shares of Humacyte in a research report on Thursday, February 27th. Finally, D. Boral Capital reissued a "buy" rating and issued a $25.00 price objective on shares of Humacyte in a research report on Wednesday, March 26th. One analyst has rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and a consensus target price of $13.71.
View Our Latest Stock Analysis on Humacyte
Institutional Investors Weigh In On Humacyte
A number of institutional investors have recently made changes to their positions in HUMA. Vanguard Group Inc. increased its stake in shares of Humacyte by 10.8% during the fourth quarter. Vanguard Group Inc. now owns 5,602,684 shares of the company's stock worth $28,294,000 after purchasing an additional 543,995 shares during the period. State Street Corp grew its holdings in Humacyte by 66.1% in the 3rd quarter. State Street Corp now owns 4,764,155 shares of the company's stock valued at $25,917,000 after buying an additional 1,895,529 shares in the last quarter. Woodline Partners LP increased its position in Humacyte by 235.7% during the 4th quarter. Woodline Partners LP now owns 2,848,802 shares of the company's stock worth $14,386,000 after buying an additional 2,000,268 shares during the period. Geode Capital Management LLC lifted its holdings in shares of Humacyte by 4.7% during the fourth quarter. Geode Capital Management LLC now owns 2,135,133 shares of the company's stock worth $10,785,000 after buying an additional 94,915 shares in the last quarter. Finally, CenterBook Partners LP acquired a new stake in shares of Humacyte during the fourth quarter worth $6,463,000. Institutional investors own 44.71% of the company's stock.
About Humacyte
(
Get Free Report)
Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to contact@insidertrades.com.
